Diffuse Large B-Cell Lymphoma Clinical Trials

A listing of 35 Diffuse Large B-Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Diffuse Large B-Cell Lymphoma

13 - 24 of 35

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 35 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT04002947

Recruiting

Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: Pe... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/12/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Diffuse Large B-Cell Lymphoma, DLBCL, NHL, Non-Hodgkin's Lymphoma

Learn More ›

Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

NCT04512716

Recruiting

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/10/2025

Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations

Conditions: B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos

Learn More ›

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

NCT05256641

Recruiting

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

03/06/2025

Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California +2 locations

Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma

Learn More ›

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05498220

Recruiting

This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back or did not improve after the treatments (rrDLBCL). This combination has not been approved by the Food and Drug Administration (FDA) for the treatment of rrDLBCL. Salvage therapy (treatment after standard treatment failed) needs to be improved. Ritu... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/04/2025

Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Conditions: Diffuse Large B-cell Lymphoma

Learn More ›

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: Valkyrie Clinical Trials /ID# 269935, Los Angeles, California +121 locations

Valkyrie Clinical Trials /ID# 269935, Los Angeles, California

Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823, Golden, Colorado

Northwest Cancer Center - Dyer Clinic /ID# 269787, Dyer, Indiana

Cancer Center of Kansas - Wichita /ID# 270117, Wichita, Kansas

Gulfport Memorial Hospital /ID# 268104, Gulfport, Mississippi

New York Medical College /ID# 265799, Valhalla, New York

Thompson Cancer Survival Ctr /ID# 242149, Knoxville, Tennessee

Community Cancer Trials Of Utah /ID# 271715, Ogden, Utah

Canberra Hospital /ID# 265312, Canberra, Australian Capital Territory

Royal Prince Alfred Hospital /ID# 263242, Sydney, New South Wales

Wollongong Hospital /ID# 244646, Wollongong, New South Wales

Toowoomba Hospital /ID# 263243, Toowoomba, Queensland

Monash Health - Monash Medical Centre /ID# 262783, Clayton, Victoria

Royal Perth Hospital /ID# 243790, Perth, Western Australia

Universitair Ziekenhuis Brussel /ID# 242574, Jette, Bruxelles-Capitale

Centre Hospitalier Epicura - site d'Hornu /ID# 265148, Boussu, Hainaut

Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 242565, Yvoir, Namur

Universitair Ziekenhuis Leuven /ID# 246671, Leuven, Vlaams-Brabant

AZ-Delta /ID# 264740, Roeselare, West-Vlaanderen

UMHAT Sveti Georgi /ID# 242905, Plovdiv, Not set

UMHAT Sveti Ivan Rilski /ID# 242389, Sofia, Not set

SHAT Hematologic Diseases /ID# 242708, Sofia, Not set

UMHAT Sveta Marina /ID# 262761, Varna, Not set

Peking University Third Hospital /ID# 242941, Beijing, Beijing

Sun Yat-Sen University Cancer Center /ID# 242712, Guangzhou, Guangdong

Guangdong Provincial People's Hospital /ID# 242942, Guangzhou, Guangdong

The Second Hospital of Hebei Medical University /ID# 242944, Shijiazhuang, Hebei

Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 242702, Wuhan, Hubei

Hubei Cancer Hospital /ID# 242963, Wuhan, Hubei

The First Affiliated Hospital of Soochow University /ID# 242939, Suzhou, Jiangsu

The First Hospital of Jilin University /ID# 242940, Changchun, Jilin

Shandong Cancer Hospital /ID# 264036, Jinan, Shandong

Tianjin Cancer Hospital /ID# 243940, Tianjin, Tianjin

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 243139, Tianjin, Tianjin

The Affiliated Cancer Hospital of Xinjiang Medical University /ID# 242966, Urumqi, Xinjiang

The second affiliated hospital of Zhejiang University school of medicine /ID# 243137, Hangzhou, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University /ID# 263951, Wenzhou, Zhejiang

Klinicka bolnica Merkur /ID# 262619, Zagreb, Grad Zagreb

Klinicki bolnicki centar Sestre milosrdnice /ID# 262620, Zagreb, Grad Zagreb

Klinicki bolnicki centar Zagreb /ID# 262617, Zagreb, Grad Zagreb

Klinicki bolnicki centar Osijek /ID# 262621, Osijek, Osjecko-baranjska Zupanija

Klinički Bolnički Centar Rijeka /ID# 266004, Rijeka, Primorsko-goranska Zupanija

Klinicki Bolnicki Centar (KBC) Split /ID# 262618, Split, Splitsko-dalmatinska Zupanija

Fakultní nemocnice Hradec Králové - Sokolská /ID# 264071, Hradec Králové, Hradec Kralove

CHRU Tours - Hopital Bretonneau /ID# 244580, Tours CEDEX 9, Indre-et-Loire

Centre Hospitalier D'Avignon /ID# 243072, Avignon, Provence-Alpes-Cote-d Azur

Centre Hospitalier de la Cote Basque /ID# 243065, Bayonne, Pyrenees-Atlantiques

CHU Poitiers - La miletrie /ID# 243074, Poitiers, Vienne

CHU de CAEN - Hopital de la Cote de Nacre /ID# 243075, Caen, Not set

Hopital Saint Vincent de Paul /ID# 243070, Lille Cedex, Not set

Institut de cancérologie Strasbourg Europe (ICANS) /ID# 264068, Strasbourg, Not set

General Hospital of Athens Laiko /ID# 262809, Athens, Attiki

University General Hospital Attikon /ID# 242041, Athens, Attiki

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 242039, Athens, Not set

General University Hospital of Thessaloniki AXEPA /ID# 242038, Thessaloniki, Not set

Theageneio Anticancer Hospital /ID# 242036, Thessaloniki, Not set

Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 262924, Pecs, Baranya

Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 262901, Gyor, Gyor-Moson-Sopron

Debreceni Egyetem-Klinikai Kozpont /ID# 242451, Debrecen, Hajdu-Bihar

Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 242468, Nyiregyhaza, Szabolcs-Szatmar-Bereg

Semmelweis Egyetem /ID# 242455, Budapest, Not set

Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 262923, Budapest, Not set

Orszagos Onkologiai Intezet /ID# 242457, Budapest, Not set

Fujita Health University Hospital /ID# 265968, Toyoake, Aichi

National Hospital Organization Shikoku Cancer Center /ID# 265977, Matsuyama, Ehime

Kyushu University Hospital /ID# 267624, Fukuoka-shi, Fukuoka

Fukushima Medical University Hospital /ID# 264667, Fukushima-shi, Fukushima

Sapporo Medical University Hospital /ID# 264928, Sapporo, Hokkaido

Kagoshima University Hospital /ID# 248259, Kagoshima-shi, Kagoshima

Tokai University Hospital /ID# 265433, Isehara, Kanagawa

Kansai Medical University Hospital /ID# 266018, Hirakata-shi, Osaka

Kindai University Hospital /ID# 265474, Osakasayama-shi, Osaka

Saitama Cancer Center /ID# 265277, Kitaadachi-gun, Saitama

University of Yamanashi Hospital /ID# 264671, Chuo, Yamanashi

Inje University - Busan Paik Hospital /ID# 262842, Busan, Busan Gwang Yeogsi

Dong-A University Medical Center /ID# 262841, Busan, Busan Gwang Yeogsi

Seoul National University Bundang Hospital /ID# 242405, Seongnam-si, Gyeonggido

Keimyung University Dongsan Hospital /ID# 262840, Daegu, Gyeongsangbugdo

Jeonbuk National University Hospital /ID# 242958, Jeonju, Jeonrabugdo

Chonnam National University Hwasun Hospital /ID# 262843, Hwasun-gun, Jeonranamdo

Seoul National University Hospital /ID# 242407, Seoul, Seoul Teugbyeolsi

Asan Medical Center /ID# 242409, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 242408, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St. Marys Hospital /ID# 242406, Seoul, Seoul Teugbyeolsi

Ulsan University Hospital /ID# 242956, Ulsan, Ulsan Gwang Yeogsi

Medisch Centrum Leeuwarden /ID# 245501, Leeuwarden, Friesland

Jeroen Bosch Ziekenhuis, locatie 's-Hertogenbosch /ID# 265204, 's-Hertogenbosch, Noord-Brabant

OLVG - Locatie Oost /ID# 263355, Amsterdam, Noord-Holland

St. Antonius Ziekenhuis /ID# 245197, Nieuwegein, Utrecht

Albert Schweitzer Ziekenhuis, locatie Dordwijk /ID# 263361, Dordrecht, Zuid-Holland

North Shore Hospital /ID# 266060, Auckland, Not set

Wellington Hospital /ID# 265966, Wellington, Not set

Pratia MCM Krakow /ID# 262882, Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 263314, Warsaw, Mazowieckie

Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 242436, Kielce, Swietokrzyskie

Aidport sp z o.o. /ID# 262766, Poznan, Wielkopolskie

Hospital da Luz /ID# 262965, Lisbon, Lisboa

Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE /ID# 262961, Porto, Not set

Unidade Local de Saude de Sao Joao, EPE /ID# 262962, Porto, Not set

Fundeni Clinical Institute /ID# 266734, Bucharest, Bucuresti

Institutul Oncologic Prof Dr I Chiricuta /ID# 243753, Cluj Napoca, Cluj

Institutul Regional de Oncologie /ID# 244367, Jassi, Iasi

Spitalul Clinic Coltea /ID# 243694, Bucharest, Not set

Clinical Hospital Center Zvezdara /ID# 263059, Belgrade, Beograd

Institute for Oncology and Radiology of Serbia /ID# 263055, Belgrade, Beograd

University Clinical Center Serbia /ID# 263057, Belgrade, Beograd

Clinical Hospital Center - Bežanijska Kosa /ID# 263053, Belgrade, Beograd

University Clinical Center Nis /ID# 263701, Niš, Nisavski Okrug

Institute for Oncology of Vojvodina /ID# 263052, Sremska Kamenica, Vojvodina

University Clinical Center Vojvodina /ID# 264138, Novi Sad, Not set

National Cancer Centre Singapore /ID# 267015, Singapore, Central Singapore

National University Hospital /ID# 264016, Singapore, Not set

Alberts Cellular Therapy /ID# 262720, Pretoria, Gauteng

Haemalife Inc. /ID# 262719, Kuilsrivier, Western Cape

National Taiwan University Hospital /ID# 243300, Taipei City, Taipei

China Medical University Hospital /ID# 242931, Taichung, Not set

Taichung Veterans General Hospital /ID# 242937, Taichung, Not set

National Cheng Kung University Hospital /ID# 243301, Tainan, Not set

Adnan Menderes University /ID# 242418, Aydin, Not set

Trakya University Medical Facu /ID# 242419, Edirne, Istanbul, Not set

Ondokuz mayis University Facul /ID# 242412, Samsun, Not set

Nottingham City Hospital /ID# 265129, Nottingham, Nottinghamshire

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

NCT05660967

Recruiting

The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.

Gender:

ALL

Ages:

75 years and above

Trial Updated:

03/03/2025

Locations: UW Cancer Center at ProHealth Care, Waukesha, Wisconsin +77 locations

UW Cancer Center at ProHealth Care, Waukesha, Wisconsin

Kepler Universitätsklinikum, Linz, Not set

LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Not set

Klinikum Wels-Grieskirchen GmbH, Wels, Not set

Institut Jules Bordet, Anderlecht, Not set

GZA Ziekenhuizen, Antwerpen, Not set

ZNA, Antwerpen, Not set

UZ Brussels, Jette, Not set

UZ Leuven, Leuven, Not set

AZ Delta, Roeselare, Not set

Vitaz, Temse, Not set

AZ Turnhout - Campus Sint-Elisabeth, Turnhout, Not set

Fakultni nemocnice Hradec Kralove, Hradec Králové, Not set

Vseobecna fakultni nemocnice v Praze, Praha 2, Not set

Fakultni nemocnice v Motole, Praha 5, Not set

CHU Angers - Hôpital Hôtel Dieu, Angers, Not set

Hôpital Henri Mondor, Créteil, Not set

Hopital Claude Huriez - CHRU Lille, Lille, Not set

Hopital de la Conception - APHM, Marseille, Not set

CHU de Nantes - Hotel Dieu, Nantes, Not set

Centre Antoine Lacassagne, Nice, Not set

Hôpital Saint-Antoine, Paris, Not set

Hôpital Saint-Louis, Paris, Not set

CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac, Not set

CHU Amiens - Hopital Sud, Salouël, Not set

CHU Tours - Hôpital Bretonneau, Tours, Not set

Universitaetsklinikum Freiburg, Freiburg, Baden Wuerttemberg

Universitaetsklinikum Aachen AOeR, Aachen, Not set

Vivantes Klinikum Neukoelln, Berlin, Not set

Universitaetsklinikum Wuerzburg, Würzburg, Not set

Clinica di Ematologia AOU Ospedali Riuniti di Ancona, Ancona, Not set

IRCCS Centro di Riferimento Oncologico, Aviano, Not set

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna, Not set

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili), Brescia, Not set

Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Not set

IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST, Meldola, Not set

IEO Istituto Europeo di Oncologia Parent, Milano, Not set

Ospedale San Raffaele, Milano, Not set

Azienda Ospedaliera Vincenzo Cervello, Palermo, Not set

AUSL Piacenza Ospedale Guglielmo da Saliceto, Piacenza, Not set

Azienda sanitaria integrata università di Trieste, Trieste, Not set

Kyushu University Hospital, Fukuoka shi, Not set

Kagoshima University Hospital, Kagoshima, Not set

Kanazawa University Hospital, Kanazawa, Not set

National Cancer Center Hospital East, Kashiwa, Not set

Cancer Institute Hospital of JFCR, Koto-Ku, Not set

Matsuyama Red Cross Hospital, Matsuyama, Not set

NHO Nagoya Medical Center, Nagoya shi, Not set

Yamagata University Hospital, Yamagata, Not set

Kindai University Hospital, Ōsaka-sayama, Not set

Keimyung University Dongsan Hospital, Daegu, Not set

National Cancer Center, Goyang-si, Not set

Jeonbuk National University Hospital, Jeonju, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej, Biała Podlaska, Not set

Pratia MCM Krakow, Kraków, Not set

Centrum Medyczne Pratia Poznan, Skorzewo, Not set

MICS Centrum Medyczne Torun, Toruń, Not set

ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Not set

Hospital San Pedro de Alcantara, Cáceres, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Hospital Universitario Nuestra Señora de Valme, Sevilla, Not set

Hospital Universitario Puerta del Mar, Sevilla, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Bristol Haematology and Oncology Centre, Bristol, Not set

Royal Marsden Hospital - Fulham, London, Not set

Churchill Hospital, Oxford, Not set

Derriford Hospital, Plymouth, Not set

Southampton General Hospital, Southampton, Not set

Royal Marsden Hospital, Sutton, Not set

Royal Cornwall Hospital NHS Trust, Truro, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840

Recruiting

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

02/27/2025

Locations: University of California LA, Los Angeles, California +43 locations

University of California LA, Los Angeles, California

Stanford University Medical Center, Stanford, California

H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Northside Hospital, Atlanta, Georgia

Northwestern University Northwestern Memorial Hospital Trans, Chicago, Illinois

Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois

University of Kansas Cancer Center, Westwood, Kansas

Mass Gen Hosp Cancer Center, Boston, Massachusetts

Montefiore Medical Center, Bronx, New York

Oregon Health Sciences University, Portland, Oregon

University of Pennsylvania Clinical, Philadelphia, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

St Davids South Austin Medical Ctr, Austin, Texas

Uni Of TX MD Anderson Cancer Cntr, Houston, Texas

Medical College of Wisconsin, Milwaukee, Wisconsin

Novartis Investigative Site, Melbourne, Victoria

Novartis Investigative Site, Wien, Not set

Novartis Investigative Site, Marseille, Not set

Novartis Investigative Site, Paris 10, Not set

Novartis Investigative Site, Pierre Benite, Not set

Novartis Investigative Site, Rennes, Not set

Novartis Investigative Site, Essen, Not set

Novartis Investigative Site, Frankfurt, Not set

Novartis Investigative Site, Koeln, Not set

Novartis Investigative Site, Leipzig, Not set

Novartis Investigative Site, Bergamo, BG

Novartis Investigative Site, Bologna, BO

Novartis Investigative Site, Milano, MI

Novartis Investigative Site, Rozzano, MI

Novartis Investigative Site, Fukuoka city, Fukuoka

Novartis Investigative Site, Sapporo city, Hokkaido

Novartis Investigative Site, Bunkyo ku, Tokyo

Novartis Investigative Site, Cordoba, Andalucia

Novartis Investigative Site, Sevilla, Andalucia

Novartis Investigative Site, Salamanca, Castilla Y Leon

Novartis Investigative Site, Badalona, Catalunya

Novartis Investigative Site, Barcelona, Catalunya

Novartis Investigative Site, Hospitalet de LLobregat, Catalunya

Novartis Investigative Site, Valencia, Comunidad Valenciana

Novartis Investigative Site, Barcelona, Not set

Novartis Investigative Site, Madrid, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

Learn More ›

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686

Recruiting

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: City of Hope Cancer Center, Duarte, California +173 locations

City of Hope Cancer Center, Duarte, California

University of California San Diego Medical Center, La Jolla, California

University of California Los Angeles, Los Angeles, California

St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

Stanford University Medical Center, Stanford, California

Stanford University, Stanford, California

Norwalk Medical Group, Norwalk, Connecticut

Northwest Georgia Oncology Centers PC, Marietta, Georgia

Northwestern University Hospital, Chicago, Illinois

Indiana University, Goshen, Indiana

Kansas University Medical Center, Westwood, Kansas

Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky

Dana Farber Cancer Center, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Battle Creek Health Systm, Battle Creek, Michigan

Karmanos Cancer Institute - Wayne State University, Detroit, Michigan

Washington University, Saint Louis, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Weill Medical College of Cornell University, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Southeastern Medical Oncology Center, Goldsboro, North Carolina

The Ohio State University- James Cancer Hospital, Columbus, Ohio

Willamette Valley Cancer Center, Eugene, Oregon

Kaiser Permanente, Portland, Oregon

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Avera Medical Group, Sioux Falls, South Dakota

MD Anderson Cancer Center - University of Texas, Houston, Texas

University of Virginia, Charlottesville, Virginia

University of Washington, Seattle, Washington

West Virginia University, Morgantown, West Virginia

University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research, Madison, Wisconsin

CEMIC Saavedra, Ciudad Autonoma Buenos Aires, Not set

Fundaleu, Ciudad de Buenos Aires, Not set

Royal Adelaide Hospital, Adelaide, Not set

John Fawkner Cancer Trial Centre, Coburg, Not set

Concord Hospital, Concord, Not set

Austin Health, Heidelberg, Not set

Peter MacCallum Cancer Institute, Melbourne, Not set

Royal Perth Hospital, Perth, Not set

Alfred Hospital, Prahran, Not set

Adventist Health Care Limited trading as San Clinical Trials Unit, Wahroonga, Not set

UZA, Antwerp, Not set

A.Z. Sint Jan, Brugge, Not set

UCL - Saint Luc, Brussels, Not set

UZ Gent - departement oncologie, Gent, Not set

UZ Leuven Gasthuisberg, Leuven, Not set

UCL Mont-Godinne, Yvoir, Not set

Ministerio da Saude Instituto Nacional do Cancer, Rio De Janeiro, Not set

Santa Casa da Misericórdia da Bahia - Hospital Santa Isabel, Salvador, Not set

Instituto de Ensino e Pesquisa São Lucas, Sao Paulo, Not set

Jewish General Hospital, Montreal, Quebec

Peking University People s Hospital, Beijing, Not set

Peking University Third Hospital, Beijing, Not set

Peking University First Hospital, Beijing, Not set

West China Hospital Sichuan University, Chengdu, Not set

Fujian Medical University, Fuzhou, Not set

Sun Yat-sen University Cancer Hospital, Guangzhou, Not set

Zhejiang University First Hospital, Hangzhou, Not set

Ruijin Hospital, Shanghai, Not set

Tangdu hospital the Fourth Military Medical, Shanxi, Not set

The First Affliated Hospital of Soochow University, Suzhou, Not set

The Institute of Hematological disease, Tianjin, Not set

Wuhan Union Hospital, Wuhan, Not set

Fundacion Santa Fe, Bogota, Not set

Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Not set

Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Brno, Not set

Fakultni nemocnice Kralovske Vinohrady - Interni hematologicka klinika, Praha 10, Not set

Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Not set

Hopital Henri Mondor, Creteil, Not set

Hôpital E. Muller, Mulhouse, Not set

Hopital Necker Enfants Malades, Paris cedex 15, Not set

HOPITAL SAINT LOUIS - Hematology / Oncology, Paris, Not set

Hopital Haut Leveque Service Maladie Du Sang, Pessac, Not set

CH LYON SUD - Hematology, Pierre Benite, Not set

CHU de Tours, Tours, Not set

Vivantes Klinikum Spandau-Klinik f. Innere Medizin Hämatologie/Onkologie/Gastroenterologie - Germany, Berlin, Not set

Universitätsklinikum Carl Gustav Carus; Med. Klinik und Poliklinik I - Hämatologische Ambulanz, Haus, Dresden, Not set

Universitätsklinikum Essen; Klinik f. Hämatologie- Germany, Essen, Not set

Justus-Liebig-Universitaet - Medizinische Klinik IV, Haematologie, Gießen, Not set

Universitätsklinikum Heidelberg Med. Klinik IV, Heidelberg, Not set

Universitätsklinikum des Saarlandes, Homburg/Saar, Not set

Gemeinschaftspraxis Dres. Uhle/Müller/Kröning/Jentsch-Ullrich - Germany, Magdeburg, Not set

OnkoNet Marburg GmbH, Marburg, Not set

Universitätsklinikum für Innere Med. III_Hämatologie, Onkologie...- Germany, Ulm, Not set

Laiko General Hospital - 1st department of Internal Medicine, Athens, Not set

G Papanikolaou Hospital of Thessaloniki, Thessalonikis, Not set

Semmelweis Egyetem, I. Belgyogyaszati Klinika, Budapest N/a, Not set

Szegedi Tudomanyegyetem II. Belgyogyaszati Klinika, Szeged, Not set

St James's Hospital, Dublin, Not set

Haemek Medical Center, Afula, Not set

Hillel Yaffe Medical Center - Oncology, Hadera, Not set

Rambam Health Care Campus, Haifa, Not set

Rabin Medical Center Beilinson Campus, Petah Tikva, Not set

Sheba Medical Center, Ramat-Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA'', Roma, Not set

A.O.Citta della Salute e della Scienza di Torino, Torino, Not set

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo ku, Not set

Hiroshima University Hospital, Hiroshima shi, Not set

Hokkaido University Hospital, Sapporo-shi, Not set

National Cancer Center, Goyang-Si, Not set

The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Not set

Oaxaca Site Management Organization S.C., Oaxaca, Not set

VU medisch centrum - Afd.Interne - INT, Amsterdam, Not set

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza, Brzozow, Not set

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Pratia MCM Krakow, Krakow, Not set

Oddzial Hematologii, Opole, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka, Slupsk, Not set

Katedra I Klinika Hematologii Nowotworow Krwi I Transplantacji Szpiku, Wroclaw, Not set

Instituto Portugues de Oncologia, Lisboa, Not set

Hospital De Santa Maria, Lisbon, Not set

Instituto Portugues de Oncologia, Porto, Not set

Auxilio Mutuo Cancer Center, San Juan, Not set

Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Not set

Chelyabinsk Regiona Onc. Center, Chelyabinsk, Not set

Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Not set

Cancer Research Center, Moscow N/a, Not set

S.P. Botkin Moscow City Clinical Hospital, Moscow, Not set

Regional Clinical Hospital n.a.Semashko, Nizhni Novgorod, Not set

Medical Scientific Radiology - Center, Obninsk, Not set

Perm Medical Sanitary Unit#1, Perm, Not set

Republican Hospital named by V.A.Baranova, Petrozavodsk, Not set

Rostov Research Institute of Oncology, Rostov-Na-Donu, Not set

Ryazan Regional Clinical Hospital, Ryazan, Not set

Leningrad region clinical hospital, Saint, Not set

Samara Region Clinical Hospital, Samara, Not set

Federal Center of Heart, Blood and Endocrinology, Sankt-Peterburg, Not set

Oncological dispensary #2, Sochi, Not set

City Clinical Oncology Dispensary, St. Petersburg, Not set

Clinical Research Institute of Hematology and Transfusiology, St.-Petersburg, Not set

Oncology Dispensary of Komi Republic, Syktyvkar, Not set

Hospital Vall d'Hebron, Barcelona N/a, Not set

Inst. Cat. Doncologia-H Duran I Reynals, L'hospitalet De Llobregat, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Infanta Leonor, Madrid, Not set

Fundacion Jimenez Diaz, Madrid, Not set

Clinica Universitaria de Navarra, Pamplona N/a, Not set

Hospital Clinico Universitario Salamanca, Salamanca, Not set

Sahlgrenska University hospital, Hematology Dept, Göteborg, Not set

Skanes universitetssjukhus, Lund, Not set

Karolinska Universitetssjukhuset Solna, Centrum för Hematologi, Stockholm, Stockholm, Not set

Changhua Cristian Hospital, Changhua County, Not set

Ankara University, Ankara, Not set

American Hospital, Istanbul, Not set

Istanbul University, Istanbul, Not set

Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Not set

Erciyes University, Kayseri, Not set

Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Not set

Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Not set

SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine, Kharkiv, Not set

Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy, Not set

State Institution Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine, Kiev, Not set

Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine, Lviv, Not set

Vinnytsya Regional Clinical Hospital named after M.I.Pirogov, Vinnitsa, Not set

University Hospitals Birmingham NHS Trust,, Birmingham, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Colchester Hospital University NHS, Colchester, Not set

Beatson West Of Scotland Cancer Centre, Glasgow, Not set

St James's Institute of Oncology, Leeds, Not set

Leicester Royal Infirmary - Haematology, Leicester, Not set

St Bartholomew's Hospital - Dept of Haematology, London, Not set

University College London Hospitals NHSFT, London, Not set

Kings College Hospital, London, Not set

Christie Hospital, Manchester, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Derriford Hospital, Plymouth, Not set

Royal Hallamshire Hospital, Sheffield, Not set

Southampton General Hospital, Southampton, Not set

Royal Marsden Hospital (Sutton), Sutton, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease

Learn More ›

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024

Recruiting

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

Gender:

ALL

Ages:

Between 65 years and 99 years

Trial Updated:

02/25/2025

Locations: Research Site, La Jolla, California +52 locations

Research Site, La Jolla, California

Research Site, Orange, California

Research Site, Stamford, Connecticut

Research Site, Jacksonville, Florida

Research Site, Des Moines, Iowa

Research Site, Lexington, Kentucky

Research Site, Beltsville, Maryland

Research Site, Towson, Maryland

Research Site, Detroit, Michigan

Research Site, Sioux Falls, South Dakota

Research Site, Lubbock, Texas

Research Site, Olympia, Washington

Research Site, Tacoma, Washington

Research Site, Barretos, Not set

Research Site, Belo Horizonte, Not set

Research Site, Brasilia, Not set

Research Site, Campinas, Not set

Research Site, Curitiba, Not set

Research Site, Florianópolis, Not set

Research Site, Goiania, Not set

Research Site, Natal, Not set

Research Site, Porto Alegre, Not set

Research Site, Recife, Not set

Research Site, Ribeirão Preto, Not set

Research Site, Rio de Janeiro, Not set

Research Site, Sao Luis, Not set

Research Site, Sao Paulo, Not set

Research Site, Sorocaba, Not set

Research Site, São José do Rio Preto, Not set

Research Site, São Paulo, Not set

Research Site, Busan, Not set

Research Site, Daegu, Not set

Research Site, Gyeongsangnam-do, Not set

Research Site, Incheon, Not set

Research Site, Jeonju-si, Not set

Research Site, Seo-gu, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, Ulsan, Not set

Research Site, San Juan, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +13 locations

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Learn More ›

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT05432635

Recruiting

This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patients with high grade B-cell non-Hodgkin lymphoma. CAR T-cells are a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T-cells are taken from a patient's blood.... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/17/2025

Locations: City of Hope Medical Center, Duarte, California

Conditions: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma

Learn More ›

Evaluation of Human Immune Responses Vaccination in Patients with Lymphoma

NCT03501576

Recruiting

This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations

Conditions: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Learn More ›

13 - 24 of 35